Melanotan I Research: Melanocortin Biology, Pigmentation Studies, and Afamelanotide

Melanotan I, also called MT-I or NDP-alpha-MSH, is the peptide design subsequently named afamelanotide. It is an alpha-melanocyte-stimulating hormone analogue containing norleucine at position 4 and D-phenylalanine at position 7. Official afamelanotide labeling describes a 13-amino-acid peptide and activity at the melanocortin-1 receptor, MC1R, which is relevant to eumelanin production.

Melanotan II is a different cyclic seven-residue analogue, as described in its own primary clinical study. Findings should not migrate between MT-I and MT-II merely because both names begin with melanotan. Receptor engagement, chemical structure, formulation, and the measured outcome remain separate parts of the evidence.

Sawyer and colleagues synthesized the modified alpha-MSH analogue and tested frog-skin darkening, mouse melanoma-cell adenylate cyclase, and tyrosinase activity. They reported prolonged biological activity and greater resistance to serum-enzyme degradation than the parent peptide. In the adenylate cyclase assay, the analogue was reported as 26 times as potent as alpha-MSH.

That numerical comparison belongs to the assay in which it was obtained. It is not a claim of a 26-fold human response. Frog melanophore pigment movement, enzyme signaling in mouse cells, and human melanin production are related research settings, but they are not interchangeable endpoints or evidence that pigmentation prevents skin cancer.

Levine and colleagues conducted a randomized, placebo-controlled, double-blind study in 28 healthy white men selected across skin-type groups. Serial chromaticity measurements tracked skin darkening after the study's purified NDP-alpha-MSH preparation or saline. The authors reported a pigmentation response in both the relatively poor-tanning and better-tanning groups.

The primary question was pigmentation over a short observation window in a selected population. The study did not establish durable prevention of ultraviolet injury or skin cancer, nor characterize every potential long-term outcome. It also used a specified research preparation, so the result cannot characterize an independently supplied material from a matching product name.

Langendonk and colleagues reported two randomized, double-blind, placebo-controlled afamelanotide implant trials in erythropoietic protoporphyria, EPP, enrolling 168 participants in total. EPP is a disorder associated with painful phototoxic reactions. The primary outcomes concerned diary-recorded time without pain in direct sunlight under each protocol's definitions, rather than pigmentation alone.

In the U.S. trial, the reported median cumulative pain-free time over six months was 69.4 hours with afamelanotide and 40.8 hours with placebo. The European trial used a different exposure window and longer observation period, so its totals should not be compared directly. The trials concerned a particular disease and implant formulation, not general cosmetic use or the performance of a research vial.

The official SCENESSE label identifies afamelanotide in a defined implant formulation for increasing pain-free light exposure in adults with a history of EPP phototoxic reactions. Its indication and clinical evidence belong to that regulated product. The labeling also identifies adverse reactions and monitoring considerations; approval is not a general declaration that every similarly named material is suitable for personal use.

For the catalog entry Melanotan 1, clarify the intended peptide identity, terminal modifications, salt or chemical form, and available lot documentation. Neither a published trial nor the shared underlying molecule establishes formulation equivalence or authenticates the vial. This selected profile provides scientific context without a tanning, sunlight-exposure, or administration protocol.